These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 31058504)

  • 1. Iterative Screening Methods for Identification of Chemical Compounds with Specific Values of Various Properties.
    Miyao T; Funatsu K
    J Chem Inf Model; 2019 Jun; 59(6):2626-2641. PubMed ID: 31058504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Profile-QSAR: a novel meta-QSAR method that combines activities across the kinase family to accurately predict affinity, selectivity, and cellular activity.
    Martin E; Mukherjee P; Sullivan D; Jansen J
    J Chem Inf Model; 2011 Aug; 51(8):1942-56. PubMed ID: 21667971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Building Quantitative Structure-Activity Relationship Models Using Bayesian Additive Regression Trees.
    Feng D; Svetnik V; Liaw A; Pratola M; Sheridan RP
    J Chem Inf Model; 2019 Jun; 59(6):2642-2655. PubMed ID: 30998343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biodiversity of small molecules--a new perspective in screening set selection.
    Petrone PM; Wassermann AM; Lounkine E; Kutchukian P; Simms B; Jenkins J; Selzer P; Glick M
    Drug Discov Today; 2013 Jul; 18(13-14):674-80. PubMed ID: 23454345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The current limits in virtual screening and property prediction.
    Hutter MC
    Future Med Chem; 2018 Jul; 10(13):1623-1635. PubMed ID: 29953247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. QSAR classification model for antibacterial compounds and its use in virtual screening.
    Singh N; Chaudhury S; Liu R; AbdulHameed MD; Tawa G; Wallqvist A
    J Chem Inf Model; 2012 Oct; 52(10):2559-69. PubMed ID: 23013546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimating the domain of applicability for machine learning QSAR models: a study on aqueous solubility of drug discovery molecules.
    Schroeter TS; Schwaighofer A; Mika S; Ter Laak A; Suelzle D; Ganzer U; Heinrich N; Müller KR
    J Comput Aided Mol Des; 2007 Sep; 21(9):485-98. PubMed ID: 17632688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of Bioactive Scaffolds Based on QSAR Models.
    Nakagawa T; Miyao T; Funatsu K
    Mol Inform; 2018 Jan; 37(1-2):. PubMed ID: 29135084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A screening pattern recognition method finds new and divergent targets for drugs and natural products.
    Wassermann AM; Lounkine E; Urban L; Whitebread S; Chen S; Hughes K; Guo H; Kutlina E; Fekete A; Klumpp M; Glick M
    ACS Chem Biol; 2014 Jul; 9(7):1622-31. PubMed ID: 24802392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and Validation of Molecular Overlays Derived from Three-Dimensional Hydrophobic Similarity with PharmScreen.
    Vázquez J; Deplano A; Herrero A; Ginex T; Gibert E; Rabal O; Oyarzabal J; Herrero E; Luque FJ
    J Chem Inf Model; 2018 Aug; 58(8):1596-1609. PubMed ID: 30010337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How diverse are diversity assessment methods? A comparative analysis and benchmarking of molecular descriptor space.
    Koutsoukas A; Paricharak S; Galloway WR; Spring DR; Ijzerman AP; Glen RC; Marcus D; Bender A
    J Chem Inf Model; 2014 Jan; 54(1):230-42. PubMed ID: 24289493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemical graphs, molecular matrices and topological indices in chemoinformatics and quantitative structure-activity relationships.
    Ivanciuc O
    Curr Comput Aided Drug Des; 2013 Jun; 9(2):153-63. PubMed ID: 23701000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bayesian molecular design with a chemical language model.
    Ikebata H; Hongo K; Isomura T; Maezono R; Yoshida R
    J Comput Aided Mol Des; 2017 Apr; 31(4):379-391. PubMed ID: 28281211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crystallographic fragment screening.
    Badger J
    Methods Mol Biol; 2012; 841():161-77. PubMed ID: 22222452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From fragment screening to potent binders: strategies for fragment-to-lead evolution.
    Eitner K; Koch U
    Mini Rev Med Chem; 2009 Jul; 9(8):956-61. PubMed ID: 19601891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmaceutical Machine Learning: Virtual High-Throughput Screens Identifying Promising and Economical Small Molecule Inhibitors of Complement Factor C1s.
    Chen JJ; Schmucker LN; Visco DP
    Biomolecules; 2018 May; 8(2):. PubMed ID: 29735903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive QSAR modeling workflow, model applicability domains, and virtual screening.
    Tropsha A; Golbraikh A
    Curr Pharm Des; 2007; 13(34):3494-504. PubMed ID: 18220786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LINGO-DL: a text-based approach for molecular similarity searching.
    Abdo A; Pupin M
    J Comput Aided Mol Des; 2021 May; 35(5):657-665. PubMed ID: 33797669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel tumor necrosis factor-α (TNF-α) inhibitors from small molecule library screening for their therapeutic activity profiles against rheumatoid arthritis using target-driven approaches and binary QSAR models.
    Zaka M; Abbasi BH; Durdagi S
    J Biomol Struct Dyn; 2019 Jun; 37(9):2464-2476. PubMed ID: 30047845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How to Prepare a Compound Collection Prior to Virtual Screening.
    Bologa CG; Ursu O; Oprea TI
    Methods Mol Biol; 2019; 1939():119-138. PubMed ID: 30848459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.